189 related articles for article (PubMed ID: 22876932)
1. Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation.
Chin CF; Tian Q; Setyawati MI; Fang W; Tan ES; Leong DT; Ang WH
J Med Chem; 2012 Sep; 55(17):7571-82. PubMed ID: 22876932
[TBL] [Abstract][Full Text] [Related]
2. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
3. Harnessing chemoselective imine ligation for tethering bioactive molecules to platinum(IV) prodrugs.
Wong DY; Lau JY; Ang WH
Dalton Trans; 2012 May; 41(20):6104-11. PubMed ID: 22426542
[TBL] [Abstract][Full Text] [Related]
4. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
[TBL] [Abstract][Full Text] [Related]
5. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
6. Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation.
Parker LJ; Italiano LC; Morton CJ; Hancock NC; Ascher DB; Aitken JB; Harris HH; Campomanes P; Rothlisberger U; De Luca A; Lo Bello M; Ang WH; Dyson PJ; Parker MW
Chemistry; 2011 Jul; 17(28):7806-16. PubMed ID: 21681839
[TBL] [Abstract][Full Text] [Related]
7. Reactivity and biological properties of a series of cytotoxic PtI2(amine)2 complexes, either cis or trans configured.
Messori L; Cubo L; Gabbiani C; Álvarez-Valdés A; Michelucci E; Pieraccini G; Ríos-Luci C; León LG; Padrón JM; Navarro-Ranninger C; Casini A; Quiroga AG
Inorg Chem; 2012 Feb; 51(3):1717-26. PubMed ID: 22225466
[TBL] [Abstract][Full Text] [Related]
8. Platinum(II) complexes with l-methionylglycine and l-methionyl-l-leucine ligands: synthesis, characterization and in vitro antitumoral activity.
Kaluderović GN; Schmidt H; Paschke R; Kalinowski B; Dietrich A; Mueller T; Steinborn D
J Inorg Biochem; 2007 Mar; 101(3):543-9. PubMed ID: 17223197
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, characterisation and chemical reactivity of mixed-ligand platinum(II) oxadiazoline complexes with potential cytotoxic properties.
Wagner G; Marchant A; Sayer J
Dalton Trans; 2010 Sep; 39(33):7747-59. PubMed ID: 20657943
[TBL] [Abstract][Full Text] [Related]
10. What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt E; Gibson D
J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
[TBL] [Abstract][Full Text] [Related]
11. Fast cleavage of a diselenide induced by a platinum(II)-methionine complex and its biological implications.
Liu Q; Wang X; Yang X; Liang X; Guo Z
J Inorg Biochem; 2010 Nov; 104(11):1178-84. PubMed ID: 20705343
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, crystal structure, studies in solution and cytotoxicity of two new fluorescent platinum(II) compounds containing anthracene derivatives as a carrier ligand.
Marqués-Gallego P; den Dulk H; Brouwer J; Kooijman H; Spek AL; Roubeau O; Teat SJ; Reedijk J
Inorg Chem; 2008 Dec; 47(23):11171-9. PubMed ID: 18975941
[TBL] [Abstract][Full Text] [Related]
13. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
14. Pyrophosphate-bridged complexes with picomolar toxicity.
Ikotun OF; Higbee EM; Ouellette W; Doyle RP
J Inorg Biochem; 2009 Sep; 103(9):1254-64. PubMed ID: 19666193
[TBL] [Abstract][Full Text] [Related]
15. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.
Wong DY; Yeo CH; Ang WH
Angew Chem Int Ed Engl; 2014 Jun; 53(26):6752-6. PubMed ID: 24844571
[TBL] [Abstract][Full Text] [Related]
16. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2014 Nov; 140():72-9. PubMed ID: 25063910
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs.
Ritacco I; Mazzone G; Russo N; Sicilia E
Inorg Chem; 2016 Feb; 55(4):1580-6. PubMed ID: 26812023
[TBL] [Abstract][Full Text] [Related]
18. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
19. The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes.
Mellor HR; Snelling S; Hall MD; Modok S; Jaffar M; Hambley TW; Callaghan R
Biochem Pharmacol; 2005 Oct; 70(8):1137-46. PubMed ID: 16139250
[TBL] [Abstract][Full Text] [Related]
20. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
